

2025 Independent Medical Education Request for Proposals

Issue Date: May 16, 2025

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposals (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

| | |
|----------------------|---|
| Eligibility Criteria | <ul style="list-style-type: none">• U.S. based education provider• Registered account in gFRS• Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.) |
| Geographical Scope | <ul style="list-style-type: none">• Educational initiatives must be U.S.-based only |

| Submission Directions | Application Process | Deadlines |
|-----------------------|---|-----------------|
| Step 1 | Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 6 weeks to complete a full grant proposal through funding.gene.com . When submitting the application, please be sure to: <ul style="list-style-type: none"> • Select the Therapeutic Area (Oncology), and Disease State (Breast Cancer) • Include "RFP May 2025 [Insert Program Title]" in the program title of the grant | June 27, 2025 |
| Step 2 | Grant decisions will be made by Genentech and decision notifications will be issued to the accredited educational provider through gFRS. | July 11, 2025 |
| Step 3 | If your grant is approved, one activity within the program must launch before October 3, 2025. | October 3, 2025 |

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

| Focus | Opportunity |
|--|---|
| <p>Therapeutic Area: Oncology</p> <p>Disease Areas: Breast Cancer</p> <p>Primary Learning Audiences: Community Oncologists Oncology Pharmacists Oncology Advanced Practice Providers Oncology Nurses</p> <p>Secondary Learning Audiences: Endocrinologists</p> <p>Support Available: Up to \$350,000</p> | <p>Phosphoinositide-3-kinase (PI3K) pathway inhibitors are established targeted therapy approaches for HR+/HER2- metastatic breast cancer (mBC) patients with PIK3CA mutations. HR+/HER2- breast cancer is the most common subtype, accounting for an estimated 70% of cases. <i>PIK3CA</i> is one of the most commonly mutated genes, found in an estimated 35-40% of these patients, and is associated with decreased survival.</p> <p>Hyperglycemia is an expected but challenging on-target effect of PI3K inhibitors (PI3Ki). Thus, practical strategies to manage hyperglycemia for community oncologists and the multidisciplinary care team are important to preserve patient access to personalized therapies.</p> <p>Genentech is seeking proposals that address educational gaps regarding data on PI3Ki treatment options and practical strategies for hyperglycemia management in the context of HR+/HER2- <i>PIK3CA</i>-mutated metastatic breast cancer to optimize patient care and outcomes.</p> <p>References:</p> <ol style="list-style-type: none"> 1. Moore H, et al. Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care. Clin Breast Cancer. 2024 Sep 28:S1526-8209(24)00276-3. https://doi.org/10.1016/j.clbc.2024.09.017 2. Llombart-Cussac A, et al. Preventing alpelisib-related hyperglycaemia in HR+/HER2- PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2024 Apr 11:71:102520. https://doi.org/10.1016/j.eclinm.2024.102520 3. SEER cancer stat facts: female breast cancer subtypes. National Cancer Institute. Bethesda, MD. Accessed November 15, 2024. https://seer.cancer.gov/statfacts/html/breast-subtypes.html |